Roche's Giredestrant Combination Shows Significant Improvement in Progression-Free Survival for ER-Positive Advanced Breast Cancer

Detailed results from the Phase III evERA Breast Cancer study, published in The New England Journal of Medicine, indicate that investigational giredestrant combined with everolimus significantly improved progression-free survival compared to standard endocrine therapy plus everolimus. This offers a potentially promising all-oral treatment option for patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer who have progressed after prior treatments.